AA
AARD

ALPS Advisors’s Aardvark Therapeutics AARD Stock Holding History

ALPS Advisors’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-17,727
Closed -$66.8K – 1233
2026
Q1 		$66.8K Sell
17,727
-150
-0.8% -$1.55K ﹤0.01% 1035
2025
Q4 		$235K Buy
+17,877
New +$223K ﹤0.01% 957

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

ALPS Advisors's AARD Position: Q2 2026 in Review

ALPS Advisors sold out of Aardvark Therapeutics (AARD) in Q2 2026, closing a stake of 17,727 shares — an estimated $66.8K sold.

ALPS Advisors first reported a position in AARD in Q4 2025 and held it in 2 quarters. The position peaked at $235K in Q4 2025. 71 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • ALPS Advisors reported no remaining Aardvark Therapeutics position as of Q2 2026 after selling out during the quarter.
  • ALPS Advisors sold 17,727 Aardvark Therapeutics shares in Q2 2026, an estimated $66.8K.
  • ALPS Advisors first reported a position in Aardvark Therapeutics in Q4 2025 and held it in 2 quarters.
  • ALPS Advisors's Aardvark Therapeutics position peaked at $235K in Q4 2025.
  • 71 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on ALPS Advisors's 13F filing for Q2 2026, filed 29 Jul 2026.